Forum Markets Inc(ETHZ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -65.19 | Insider Own | 55.28% | Shs Outstand | 16.0M | Perf Week | -2.22% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 8.5M | Perf Month | -26.92% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 26.29% | Short Float | 34.72% | Perf Quarter | -65.19% |
| Income | -0.23B | P/S | 16.33 | EPS this Y | - | Inst Trans | 14.93% | Short Ratio | 3.85 | Perf Half Y | -88.15% |
| Sales | 0.00B | P/B | 0.13 | EPS next 5Y | - | ROA | -42.57% | Short Interest | 2.95M | Perf YTD | -27.96% |
| Book/sh | 27.78 | P/C | 0.12 | EPS past 3/5Y | 60.23% 55.37% | ROE | -96.7% | 52W High | -97.98% ($174.60) | Perf Year | -69.83% |
| Cash/sh | 29.4 | P/FCF | - | Sales past 3/5Y | - | ROIC | -23.91% | 52W Low | 18.06% ($2.99) | Perf 3Y | -99.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -35.5% | Gross Margin | - | Volatility(W/M) | 6.88% 8.07% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | 13.38 | Sales Y/Y TTM | - | Oper. Margin | -5498.66% | ATR (14) | 0.34 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.07 | EPS Q/Q | -96.95% | Profit Margin | -5475.49% | RSI (14) | 39.33 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.07 | Sales Q/Q | - | SMA20 | -0.87% ($3.56) | Beta | 1.15 | Target Price | - |
| Payout | - | Debt/Eq | 1.23 | Earnings | 2025/11/14 | SMA50 | -23.77% ($4.63) | Rel Volume | 0.56 | Prev Close | $3.82 |
| Employees | 3 | LT Debt/Eq | 1.11 | EPS/Sales Surpr. | - | SMA200 | -78.74% ($16.6) | Avg Volume(3M) | 0.77M | Price | $3.53 |
| IPO | 2017/6/27 | Option/Short | Yes/Yes | Trades | 2329 | Volume | 428,152 | Change | -7.59% |
🔬 Forum Market (ETHZ) is a promising U.S. healthcare venture company that is actively generating results in the research and development of high-growth biotechnology, including next-generation immuno-oncology drugs and therapeutic candidates.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
ETHZ has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,633. Peers typically go for $204.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
34.7% of the float is sold short.
Tap to view numbers
It ranks #392 of 595 in the industry
Based on market cap of $67M.
FAQ
What kind of company is ETHZ?
ETHZ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ETHZ?
The market cap of ETHZ is approximately $67M, ranking 4,732 within its sector.
What is the 52-week high and low for ETHZ?
ETHZ has recorded a 52-week high of $174.60 and a low of $2.99.
